Join
Live feed
·
PRReleasevia Quantisnow
Editas Medicine Inc. logo

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
EDIT· Editas Medicine Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EDIT (Editas Medicine Inc.) and more on Quantisnow.